ArticleBMC neurology2026
Prevalence and development of sarcopenia and malnutrition in neurological patients during inpatient rehabilitation: a prospective cohort with an embedded, cross-sectional concurrent validity study for regional sarcopenia measurements.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence indicates that neurological patients exhibit high levels of sarcopenia due to disease, inactivity and malnutrition, which itself often occurs due to feeding impairments. Knowledge about the evolution of these pathologies during inpatient rehabilitation is lacking. Additionally, current gold-standard measures assess whole-body sarcopenia although regional presentations may be common in neurological patients. The aims of this study are to investigate the prevalence and development of sarcopenia and malnutrition over six months during in-patient neurological rehabilitation using 1.) gold-standard measurements (EWGSOP2 Criteria) and 2.) regional measurements (segmental BIA) for sarcopenia, to evaluate the concurrent-validity.
methodsPatients admitted to a neurological rehabilitation clinic between April-June 2023 were assessed for eligibility and, if eligible, followed for six months. Those eligible were screened for malnutrition and sarcopenia risk at admission, three weeks, three months, and six months or three days prior to discharge, those screening positive underwent diagnostic testing. Sarcopenia was assessed using gold-standard and regional (index) tests.
resultsFrom 105 individuals admitted, 45 (48.9% male) were included and analyzed. Malnutrition: baseline prevalence was 31.1% (95% CI 18.2-46.6), which dropped to 0% (95% CI 0-28.5) after 6 months. Sarcopenia: baseline prevalence was 37.8% (95% CI 23.8-53.5), which dropped to 26.2% (95% CI 13.9-42) at 3 weeks and did not change again. The baseline prevalence of regional sarcopenia was higher (42.2%), but the trends were similar. Regional measurements demonstrated high sensitivity (100%), specificity (93-100%) and levels of agreement (k=0.91-1.0) compared to gold standard.
conclusionMalnutrition and sarcopenia are common in neurological patients. Regional sarcopenia tests have similar validity to whole-body assessments and can find asymmetric sarcopenia, which makes it useful for targeted rehabilitation in neurological patients. CLINICAL TRIAL NUMBER: Registered at ClinicalTrials.gov with the identifier 2022-01098.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.